The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

"Casgevy offers an effective cure for transfusion-dependent beta thalassaemia for people without a stem cell donor," she added, whilst pointing out there is also a desperate need for new options ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

The company’s first approved product, CASGEVY, is a groundbreaking CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion-dependent beta-thalassemia. This historic approval in ...

I was expecting to see some details of Casgevy's revenue performance since it was approved to treat Sickle Cell Disease (“SCD”) in December last year, and to treat transfusion dependent beta ...

Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta thalassemia — in the United States, Europe and several other countries.

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...